IMS CORE lab teams up with Cristal Therapeutics

Cristal Therapeutics has announced that it has secured a Horizon 2020 grant. This allows the company to further develop the CriPec Nanomedicine Platform. This will be done in collaboration with the IMS CORE lab at Maastricht University’s M4I Division of Imaging Mass Spectrometry.

Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases. The ICARUS project will be carried out in close collaboration with the IMS CORE lab at the division of Imaging Mass Spectrometry, ​where CriPec® nanoparticle microlocalisation and drug release in tumours will be evaluated. Mass spectrometry imaging, technology together with Cristal Therapeutics’ expert team, will provide critical new insights to optimally design CriPec® nanomedicines with the aim of achieve superior therapeutic profiles.​ 

The project at M4I will be led by Dr. Berta Cillero Pastor and by Prof. Ron Heeren.

For more details, read the full article on the Cristal Therapeutics website: http://cristaltherapeutics.com/cristal-therapeutics-awarded-horizon-2020-grant-to-further-develop-the-cripec-nanomedicine-platform/

Also read

  • Green light for UM participation in unique YUFE bachelor programme

    The UM can start as a degree awarding partner in the new unique bachelor programme Urban Sustainability Studies offered by YUFE (Young Universities for the Future of Europe), an alliance of ten European universities. This week, the UM received a positive outcome of the macro due diligence assessment...

    YUFE logo
  • Study Smart gets Dutch Education Premium

    Maastricht University's (UM) interfaculty educational innovation project Study Smart is one of the three winners of the Dutch Education Premium 2025. This was announced on Tuesday during the Comenius festival in The Hague. 

    Winners Onderwijspremie 2025